Ableson et al.16 compared CHIP carriers who never developed acute myeloid leukemia (AML) with CHIP where individuals subsequently developed AML, and they found that the number of mutations, the mutational burden and the size of the larger driver clone were associated with the risk of progression to AML. This evidence concerns the gene STUB1 and acute myeloid leukemia.